How are ORKA strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ORKA strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 80.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,725.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a ORKA strangle?

The breakeven for the ORKA strangle priced on this page is roughly $87.75 and $132.25 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ORKA market-implied 1-standard-deviation expected move in the same options snapshot is approximately 23.16%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current ORKA implied volatility affect this strangle?

ORKA ATM IV is at 80.80% with IV rank near 13.57%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

ORKA Strangle Strategy

ORKA (Oruka Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

ORKA (Oruka Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $6.48B, a beta of -0.39 versus the broader market, a 52-week range of 14.03-109.415, average daily share volume of 1.6M, a public-listing history dating back to 1997, approximately 68 full-time employees. These structural characteristics shape how ORKA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of -0.39 indicates ORKA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. ORKA pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.

What is a strangle on ORKA?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

ORKA snapshot

As of August 14, 2026, spot at $109.93, ATM IV 80.80%, IV rank 13.57%, expected move 23.16%. The strangle on ORKA below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this strangle structure on ORKA specifically: ORKA IV at 80.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a ORKA strangle, with a market-implied 1-standard-deviation move of approximately 23.16% (roughly $25.46 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ORKA expiries trade a higher absolute premium for lower per-day decay. Position sizing on ORKA should anchor to the underlying notional of $109.93 per share and to the trader's directional view on ORKA stock.

ORKA strangle setup

The ORKA strangle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ORKA at $109.93 on that close, the first option leg uses a $115.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ORKA chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ORKA shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$115.00	$8.35
Buy 1	Put	$105.00	$8.90

ORKA strangle risk and reward

Net Premium / Debit: -$1,725.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$1,725.00
Breakeven(s): $87.75, $132.25
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

ORKA strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on ORKA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$8,774.00
$24.32	-77.9%	+$6,343.50
$48.62	-55.8%	+$3,912.99
$72.93	-33.7%	+$1,482.49
$97.23	-11.6%	-$948.01
$121.54	+10.6%	-$1,071.49
$145.84	+32.7%	+$1,359.02
$170.15	+54.8%	+$3,789.52
$194.45	+76.9%	+$6,220.02
$218.76	+99.0%	+$8,650.52

When traders use strangle on ORKA

Strangles on ORKA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ORKA chain.

ORKA thesis for this strangle

The market-implied 1-standard-deviation range for ORKA extends from approximately $84.47 on the downside to $135.39 on the upside. A ORKA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ORKA IV rank near 13.57% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ORKA at 80.80%. As a Healthcare name, ORKA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ORKA-specific events.

ORKA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ORKA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ORKA alongside the broader basket even when ORKA-specific fundamentals are unchanged. Always rebuild the position from current ORKA chain quotes before placing a trade.

Frequently asked questions

What is a strangle on ORKA?: A strangle on ORKA is the strangle strategy applied to ORKA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ORKA stock at $109.93 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed ORKA chain strike and the premiums come straight from that session's bid/ask midpoint.
How are ORKA strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ORKA strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 80.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$1,725.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ORKA strangle?: The breakeven for the ORKA strangle priced on this page is roughly $87.75 and $132.25 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ORKA market-implied 1-standard-deviation expected move in the same options snapshot is approximately 23.16%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on ORKA?: Strangles on ORKA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ORKA chain.
How does current ORKA implied volatility affect this strangle?: ORKA ATM IV is at 80.80% with IV rank near 13.57%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.